Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Moodys
Johnson and Johnson
Mallinckrodt
Medtronic

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Nomegestrol

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Nomegestrol?

Nomegestrol is an investigational drug.

There have been 15 clinical trials for Nomegestrol. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2013.

The most common disease conditions in clinical trials are Dysmenorrhea, Sclerosis, and Recurrence. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Mahidol University, and CRS Mannheim GmbH.

There are one hundred and twenty-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Nomegestrol
TitleSponsorPhase
Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol AcetateGrĂ¼nenthal S.A.Phase 1
Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol AcetateGrĂ¼nenthal GmbHPhase 1
Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal ContraceptionMahidol UniversityPhase 4

See all Nomegestrol clinical trials

Clinical Trial Summary for Nomegestrol

Top disease conditions for Nomegestrol
Top clinical trial sponsors for Nomegestrol

See all Nomegestrol clinical trials

US Patents for Nomegestrol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nomegestrol   Start Trial Methods and devices for minimally-invasive delivery of radiation to the eye Salutaris Medical Devices, Inc. (Tucson, AZ)   Start Trial
Nomegestrol   Start Trial Methods for treatment of incontinence associated with sexual activity Allergan, Inc. (Irvine, CA)   Start Trial
Nomegestrol   Start Trial Formulations and methods for vaginal delivery of antiprogestins   Start Trial
Nomegestrol   Start Trial Isoflavonoid compounds and methods for the treatment of cancer MEI PHARMA, INC. (San Diego, CA)   Start Trial
Nomegestrol   Start Trial Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen Arstat, Inc. (Flemington, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nomegestrol

Drugname Country Document Number Estimated Expiration Related US Patent
Nomegestrol Argentina 077545 2028-01-07   Start Trial
Nomegestrol Argentina 078871 2028-01-07   Start Trial
Nomegestrol Australia 2009204223 2028-01-07   Start Trial
Nomegestrol Australia 2015204094 2028-01-07   Start Trial
Nomegestrol Australia 2017203380 2028-01-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Medtronic
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.